Cargando…
Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer
BACKGROUND: We investigated the prognostic impact of changes in serum CA125 levels during the first 3 months of therapy in ovarian cancer. METHODS: A case series of 170 ovarian cancer patients treated at Cancer Treatment Centers of America. Based on CA125 levels at baseline and 3 months, patients we...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2959041/ https://www.ncbi.nlm.nih.gov/pubmed/20939881 http://dx.doi.org/10.1186/1757-2215-3-22 |
_version_ | 1782188426076880896 |
---|---|
author | Gupta, Digant Lammersfeld, Carolyn A Vashi, Pankaj G Braun, Donald P |
author_facet | Gupta, Digant Lammersfeld, Carolyn A Vashi, Pankaj G Braun, Donald P |
author_sort | Gupta, Digant |
collection | PubMed |
description | BACKGROUND: We investigated the prognostic impact of changes in serum CA125 levels during the first 3 months of therapy in ovarian cancer. METHODS: A case series of 170 ovarian cancer patients treated at Cancer Treatment Centers of America. Based on CA125 levels at baseline and 3 months, patients were classified into 4 groups: 1) Normal (0-35 U/ml) at baseline and three months; 2) High (>35 U/ml) at baseline, normal at three months; 3) Normal at baseline, high at 3 months; 4) High at baseline and three months. Kaplan Meier method was used to calculate survival across the 4 categories. RESULTS: Of 170 patients, 36 were newly diagnosed while 134 had received prior treatment. 25 had stage I disease at diagnosis, 15 stage II, 106 stage III and 14 stage IV. The median age at presentation was 54.2 years (range 23.1 - 82.5 years). At baseline, 31 patients had normal (0-35 U/ml) serum CA125 levels while 139 had high (>35 U/ml) levels. At 3 months, 59 had normal while 111 had high levels. Patients with a reduced CA125 at 3 months had a significantly better survival than those with increased CA125 at 3 months. Patients with normal values of CA125 at both baseline and 3 months had the best overall survival. CONCLUSIONS: These data show that reduction in CA125 after 3 months of therapy is associated with better overall survival in ovarian cancer. Patients without a significant decline in CA125 after 3 months of therapy have a particularly poor prognosis. |
format | Text |
id | pubmed-2959041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29590412010-10-22 Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer Gupta, Digant Lammersfeld, Carolyn A Vashi, Pankaj G Braun, Donald P J Ovarian Res Research BACKGROUND: We investigated the prognostic impact of changes in serum CA125 levels during the first 3 months of therapy in ovarian cancer. METHODS: A case series of 170 ovarian cancer patients treated at Cancer Treatment Centers of America. Based on CA125 levels at baseline and 3 months, patients were classified into 4 groups: 1) Normal (0-35 U/ml) at baseline and three months; 2) High (>35 U/ml) at baseline, normal at three months; 3) Normal at baseline, high at 3 months; 4) High at baseline and three months. Kaplan Meier method was used to calculate survival across the 4 categories. RESULTS: Of 170 patients, 36 were newly diagnosed while 134 had received prior treatment. 25 had stage I disease at diagnosis, 15 stage II, 106 stage III and 14 stage IV. The median age at presentation was 54.2 years (range 23.1 - 82.5 years). At baseline, 31 patients had normal (0-35 U/ml) serum CA125 levels while 139 had high (>35 U/ml) levels. At 3 months, 59 had normal while 111 had high levels. Patients with a reduced CA125 at 3 months had a significantly better survival than those with increased CA125 at 3 months. Patients with normal values of CA125 at both baseline and 3 months had the best overall survival. CONCLUSIONS: These data show that reduction in CA125 after 3 months of therapy is associated with better overall survival in ovarian cancer. Patients without a significant decline in CA125 after 3 months of therapy have a particularly poor prognosis. BioMed Central 2010-10-12 /pmc/articles/PMC2959041/ /pubmed/20939881 http://dx.doi.org/10.1186/1757-2215-3-22 Text en Copyright ©2010 Gupta et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Gupta, Digant Lammersfeld, Carolyn A Vashi, Pankaj G Braun, Donald P Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer |
title | Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer |
title_full | Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer |
title_fullStr | Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer |
title_full_unstemmed | Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer |
title_short | Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer |
title_sort | longitudinal monitoring of ca125 levels provides additional information about survival in ovarian cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2959041/ https://www.ncbi.nlm.nih.gov/pubmed/20939881 http://dx.doi.org/10.1186/1757-2215-3-22 |
work_keys_str_mv | AT guptadigant longitudinalmonitoringofca125levelsprovidesadditionalinformationaboutsurvivalinovariancancer AT lammersfeldcarolyna longitudinalmonitoringofca125levelsprovidesadditionalinformationaboutsurvivalinovariancancer AT vashipankajg longitudinalmonitoringofca125levelsprovidesadditionalinformationaboutsurvivalinovariancancer AT braundonaldp longitudinalmonitoringofca125levelsprovidesadditionalinformationaboutsurvivalinovariancancer |